Skip to main content

Pharma’s defenders in Congress will blunt drug-price reform, experts say

Experts say that despite the lip service paid to the issue by presidents and many lawmakers, there likely remain too many stout defenders of pharmaceutical companies in Congress to enact reforms that will meaningfully reduce revenues for the industry overall.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.